Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      In Combination with a GLP-1, ERX Pharmaceuticals' First-in-Class Oral Leptin Sensitizer, ERX1000, Showed Significantly Enhanced Weight Loss, Improved Overall Metabolic Health, and Increased Muscle Strength in Diet-Induced Obese Mice


      News provided by

      ERX Pharmaceuticals Inc.

      Nov 16, 2026, 09:00 ET

      Share this article

      Share this article


      • According to a new study, the combination therapy resulted in a placebo-corrected body weight reduction of 36% over five weeks, compared to 14% for semaglutide alone and 18% for ERX1000
      • Combination therapy also improved muscle strength 32% versus the placebo, while increasing the lean mass and lean-to-fat ratio and improving oral glucose tolerance and insulin sensitivity
      • As a monotherapy, ERX1000 is currently in a Phase 2a clinical trial after promising results in earlier studies

      CAMBRIDGE, Mass., Nov. 16, 2026 /PRNewswire/ -- ERX Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative treatments for obesity and related diseases, today announced positive results for its orally administered, small-molecule leptin sensitizer, ERX1000, when combined with a GLP-1 receptor agonist semaglutide (SEMA) in diet-induced obese mice.

      Dr. Louis Aronne, MD, FTOS, of the Comprehensive Weight Control Center of Weill Cornell Medicine in New York, presented the findings on November 15 at the Obesity Society's ObesityWeek 2026 conference in Washington, D.C. A renowned authority on obesity and its treatment, Dr. Aronne is a member of ERX Pharmaceuticals' board of directors and chair of its scientific advisory board.

      The study of diet-induced obese mice found that a therapy combining ERX1000 with semaglutide showed synergistic results, outperforming either monotherapy and the sum of the individual treatment effects. The combined treatment achieved a placebo-corrected body weight reduction of 36% vs. baseline after 35 days of treatment, compared with 18% for ERX1000 alone and 14% for semaglutide alone.

      The combination therapy also found improved glucose/insulin sensitivity, reduced fat mass and lipid levels in plasma and in liver, and improved muscle strength and lower intramuscular adipocyte infiltration.

      Leptin a Key to Healthy and Sustainable Weight Loss

      Leptin is a hormone that mediates body weight by signaling to the brain whether to eat and how much energy to expend. Leptin resistance contributes to obesity by impairing appetite regulation and energy homeostasis. ERX1000 is a novel leptin sensitizer designed to restore leptin responsiveness, thereby suppressing food intake and blocking reduction of energy expenditure with weight loss.

      The results of this new study suggest that ERX1000 may help patients taking semaglutide prevent the body from fighting back against weight loss. Semaglutide is the active ingredient in weight-loss and diabetes treatments Wegovy and Ozempic. ERX1000 is currently being investigated in a Phase 2a human clinical trial to assess its safety and tolerability in men and women for the treatment of obesity.

      "These findings support leptin sensitization as a potential strategy to enhance the metabolic efficacy of GLP-1 receptor agonist therapy in obesity," Dr. Aronne said. "We believe this therapy could play a role in the fight against obesity moving forward."

      "Among other benefits, the combination therapy may mean patients can lower their GLP-1 dose and reduce accompanying side effects," Dr. Aronne added.

      Teo Uysal, CEO of ERX Pharmaceuticals, said: "Resistance to the hormone leptin interrupts proper signaling to the brain regarding how much to eat and when to stop. By overcoming leptin resistance, it appears we may be able to restore more normal regulation of appetite and other metabolic benefits."

      "Moreover," Uysal added, "with our Phase 2a study currently underway, we are hopeful that additional positive results regarding ERX1000 are yet to come."

      In the in vivo study, performed by Physiogenex in France, the combination therapy showed a 39% reduction in food intake compared with 9% for semaglutide alone and 3% for ERX1000 alone. It also showed a greater effect in improving oral glucose tolerance and insulin sensitivity and no decline in body-weight-adjusted energy expenditure.

      The combination therapy increased lean mass and lean-to-fat ratio, improved muscle strength in a weight-normalized grip strength test (32%, versus 25% for ERX1000 alone and 8% for semaglutide alone), reduced plasma total cholesterol, and strongly reduced liver-fat and liver-lipids levels (-78% hepatic total cholesterol vs. placebo).

      Leptin Sensitization: A New Approach

      Leptin sensitization is a new approach to obesity that ERX Pharmaceuticals is developing. People with obesity have sufficient leptin, and resistance to the hormone, rather than the amount of it in the system, is a crucial issue in body-weight regulation leading to an increase in weight. This is similar to insulin resistance in type 2 diabetics. Further, an exaggerated reduction in serum leptin levels that occurs with weight loss may contribute to the plateau phenomenon limiting the amount of weight lost with other treatments.

      ERX Pharmaceuticals previously completed two successful Phase 1 clinical trials for ERX1000. The initial trial showed dose-dependent weight loss with no serious nausea or gastrointestinal side effects over a one-month treatment period. The second trial explored a weekly dosing regimen.

      The Phase 2a trial in individuals with obesity is expected to be completed by the second half of 2027.

      ERX1000 has also received Orphan Drug Designation for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease with no approved drugs available. PWS is characterized by hyperphagia—an extreme insatiable appetite or increased hunger that persists even after a full meal.

      The abstract of the study presented at ObesityWeek can be found here.

      About ERX Pharmaceuticals Inc.

      ERX Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and clinical development of innovative treatments for obesity and related diseases. ERX's research program is based on a new understanding of the role of the hormone leptin in appetite control and energy expenditure, and the potential for leptin sensitizers to overcome the state of leptin resistance in obesity and related diseases.

      ERX Pharmaceuticals was founded in 2014, based on discoveries by researchers at Boston Children's Hospital and Harvard Medical School. The company is based in Cambridge, Massachusetts.

      For more information, visit erxpharmaceuticals.com.

      MEDIA CONTACT:
      PRCG | Haggerty LLC
      (212) 683-8100
      Lucy O'Brien, [email protected]
      Thom Weidlich, [email protected]

      SOURCE ERX Pharmaceuticals Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.